Current guidelines for many critical illnesses recommend targeting a MAP of 65 mm Hg, with consideration of higher MAPs in older patients with chronic HTN. Recent literature, however, suggests increased mortality in older patients who are exposed to larger quantities of vasopressor medications. In this podcast, we do a deep dive into the recently published 65 Trial, which sought to evaluate the effect of permissive hypotension in older patients with vasodilatory hypotension.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
More than 350,000 cardiac arrests occur each year in North America. Approximately 100,000 of these arrests are due to shockable rhythms. Unfortunately, many patients...
REBOA is a relatively new and novel technique that in animal studies has demonstrated benefit in controlling hemorrhage. However, the evidence for the efficacy...
ED Pharmacist extraordinaire Jill Logan joins CCPEM to discuss the use of high-dose nitroglycerin in patients with acute cardiogenic pulmonary edema. Is it safe? ...
